TL;DR
Brightening wins short-term. Microbiome wins decade-long. The brightening category is the largest segment in facial skincare globally because the results are visible in weeks and the marketing photographs well. Microbiome support is slower, harder to photograph, and the science is younger but pointing in a clear direction. Elelaf built the hero stack around microbiome resilience and gave up the easier brightening sale. The tradeoff is honest and the reasoning is in this piece.
The first product line I had on paper for Elelaf in 2022 was a brightening trio. Vitamin C serum, tranexamic acid spot treatment, niacinamide moisturizer. Easy to brief, easy to market, big category, clean before-and-after photography. I scrapped it after eight months of formulator conversations and a long read of the microbiome literature. The pivot was the most consequential decision the brand has made, and I want to write it down properly.
What the brightening category actually is
Brightening in skincare is shorthand for two related but distinct goals: reducing existing hyperpigmentation (post-inflammatory marks, melasma, sun damage) and producing a more uniform, luminous skin appearance overall. The category includes vitamin C, niacinamide, tranexamic acid, kojic acid, alpha arbutin, hydroquinone (prescription in most markets), and a long tail of secondary actives.
The commercial appeal is direct. Visible result in four to twelve weeks. Photographs well for marketing. Universal appeal across skin tones and ages. Pricing power is strong because consumers will pay for measurable lightening. The category alone represents roughly $20 billion globally as of 2024 estimates, and it is growing.
The clinical case for the actives is solid. The dermatology literature on vitamin C and tranexamic acid is well established. Real benefit, real mechanisms, real consumer satisfaction. This is not a piece arguing against the category. It is a piece explaining why we did not build there.
The microbiome case, in plain language
The skin microbiome is the community of bacteria, fungi, and other microorganisms that live on the skin surface and within the upper layers of the stratum corneum. The dominant species include Cutibacterium acnes, Staphylococcus epidermidis, Malassezia species, and a long tail of less common organisms. The community varies by body site, individual genetics, age, and environment.
The microbiome’s functions, increasingly documented over the past decade, include modulating skin pH, producing antimicrobial peptides that protect against pathogens, supporting the immune education of the skin’s local immune cells, contributing to lipid composition in the stratum corneum, and influencing skin barrier function directly.
A 2021 review in Nature Reviews Microbiology documented the increasingly clear connection between microbiome disruption and several common skin conditions: atopic dermatitis, acne, rosacea, and certain aging-related changes. The mechanisms are causally implicated, not just correlated.
Microbiome-supportive skincare is the category that emerged from this research. Postbiotic ingredients (the metabolic products of bacteria, used as actives without live cells), prebiotic ingredients (substrates that selectively feed beneficial species), and barrier-supporting formulations that do not disrupt the microbiome through aggressive surfactants or high-alcohol vehicles.
Why we chose this category
The reasoning had three components.
First, the long-term case. Microbiome health is upstream of many of the visible problems that brightening addresses downstream. A resilient microbiome reduces inflammatory acne, which reduces post-inflammatory hyperpigmentation, which reduces the need for spot-brightening interventions. The work is structural rather than corrective.
Second, the editorial fit. Slow skincare is about long-arc work. Microbiome resilience is the textbook slow-arc work. The two framings reinforce each other. Brightening can be slow but is more often sold as a six-week transformation. The cultural rhythm of the category does not match our editorial rhythm.
Third, the differentiation. The brightening category is crowded with established players: SkinCeuticals, Vichy, La Roche-Posay, plus the budget tier of The Ordinary, Naturium, and several private labels. The microbiome category was less crowded in 2022 and remains a place where smaller brands with editorial focus can compete on substance.
None of these reasons is bulletproof. The brightening case for the brand was also defensible. We made the call on the editorial fit weighted most heavily, and we accept the cost of being in a less commercially proven category.
The contrarian section: brightening is not the enemy, and we use brightening actives too
I want to be careful with the framing. This is not a piece arguing that brightening is shallow or that consumers who want lighter skin or more uniform tone are pursuing the wrong goal. The desire for clearer skin tone is universal and reasonable. The clinical actives that produce it are competent.
Our products contain niacinamide, which is both a microbiome-supportive ingredient and a brightening agent. The Microbiome Glow Serum includes ingredients that produce visible radiance over twelve weeks, which is a brightening outcome by any honest measure. The line is not anti-brightening. It is built so that the brightening effect is a downstream consequence of microbiome and barrier health, not the upstream marketing claim.
The contrarian honesty: a customer who specifically wants to fade a melasma patch should pair our products with a dermatologist-prescribed tranexamic acid or hydroquinone. Our line does not directly compete with those clinical interventions for severe hyperpigmentation. The honest framing is that we serve the maintenance and resilience layer, not the spot-correction layer.
What we gave up
The commercial cost has been measurable. Microbiome marketing is harder. The before-and-after photography is less dramatic at twelve weeks because the work is structural rather than corrective. The retail buyers who responded to brightening pitches with budgets respond to microbiome pitches with skepticism, partly because the category is younger and partly because the metrics are less photogenic.
The customer education burden is higher. A first-time customer needs more context for why a postbiotic complex is useful than for why a vitamin C serum is useful. The marketing content has to do more work. The return on each piece of content is lower in immediate sales, higher in long-term loyalty.
The pace of category proof is slower. Brightening has thirty years of clinical literature. Microbiome skincare has perhaps eight to twelve years of serious literature. The evidence base is growing but it is younger. A buyer who wants the strongest possible clinical case will still find brightening more defensible than microbiome.
These are real costs and we accept them.
What this means for the reader
If you want fast, visible lightening of a specific spot, our products are not the most direct tool. Consider tranexamic acid plus vitamin C with a sunscreen routine, or a dermatology consultation. We will not be offended.
If you want a routine that maintains skin resilience over years, reduces inflammatory flares, supports the barrier, and incidentally produces a more uniform tone over twelve to twenty-four weeks, our hero stack is built for that work.
The two goals are different. The same person can have both at different life stages. The slow-skincare argument is that the maintenance work matters more cumulatively than the correction work, and most adults do too much correction and too little maintenance. This connects to the slow skincare manifesto and the no niacinamide-only serum editorials, which share the same logical thread.
What the next five years look like for the microbiome category
The honest forecast: the category will mature. The clinical evidence base will grow. More brands will enter. The marketing claims will get tighter as regulatory bodies catch up. Some of the early postbiotic ingredients will turn out to be less effective than initially claimed and will get replaced by better-characterized successors.
The brands that survive this maturation will be the ones that resisted the temptation to overpromise in the early years. We are trying to be one of those. The cost is a lower growth rate in the short term. The benefit is that we are not building on claims we will have to walk back when the science gets sharper.
The brightening category will continue to be larger and more commercially attractive. We will continue not to build there.
FAQ
Does microbiome skincare actually work? The evidence base is growing and credible. The effect size on specific outcomes (barrier function, inflammatory acne, sensitivity) is documented. The marketing claims sometimes get ahead of the data; the data is real but younger than the brightening literature.
Can I combine microbiome products with brightening products? Yes, and many readers do. The Microbiome Glow Serum layers well with a vitamin C in the morning or a tranexamic acid at night. The microbiome support reduces the inflammatory response that the brightening actives sometimes produce.
What is the difference between probiotic, prebiotic, and postbiotic skincare? Probiotic uses live cells, which is technically difficult to stabilize and rarely the strongest formulation choice. Prebiotic uses substrates that feed beneficial bacteria. Postbiotic uses the metabolic products of bacteria as the active ingredient. Postbiotic is the dominant approach in current credible microbiome skincare.
Will you ever make a dedicated brightening product? Possibly, but only if we can build one that fits the editorial position. A vitamin C serum with microbiome-supportive formulation is more likely than a standalone tranexamic acid spot treatment.
Is microbiome marketing just a trend? The marketing is partly trend-driven. The underlying science is structural. The trend will fade; the science will not.
For related reading, see the no niacinamide-only serum editorial and the slow skincare manifesto.
Tag hub: More on microbiome-focused formulation
Sources
Byrd AL et al. The human skin microbiome. Nature Reviews Microbiology, 2018 (updated 2021). Boxberger M et al. Challenges in microbiome skincare research. Microorganisms, 2021. Draelos ZD. Postbiotic skincare and clinical outcomes. Journal of Clinical and Aesthetic Dermatology, 2022.